Eslicarbazepine acetate - Bial

Drug Profile

Eslicarbazepine acetate - Bial

Alternative Names: Aptiom; BIA 2-093; ESL; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bial
  • Developer BIAL; Eisai Co Ltd; Sunovion Pharmaceuticals
  • Class Acetates; Amides; Analgesics; Antiepileptic drugs; Dibenzazepines; Esters; Small molecules
  • Mechanism of Action Sodium channel antagonists; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase II Migraine
  • Discontinued Bipolar disorders; Fibromyalgia; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 28 Jun 2018 Launched for Partial epilepsies (Monotherapy) in Canada (PO)
  • 27 Jun 2018 Registered for Partial epilepsies (Monotherapy) in Canada (PO)
  • 27 Feb 2018 Eslicarbazepine acetate market licensed to Whanin Pharmaceuticals in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top